"Anti-Sema3a Antibodies And Their Uses For Treating A Thrombotic Disease Of The Retina" in Patent Application Approval Process (USPTO 20240228600).

A patent application has been filed for the use of anti-Sema3A antibodies in treating thrombotic diseases of the retina, specifically retinal vein occlusion (RVO). The inventors have discovered that Sema3A, a protein involved in vessel pathfinding, inhibits vascular regeneration of the retina and promotes pathological neovascularization. The application discusses how anti-Sema3A antibodies can target specific regions of the Sema3A protein to improve revascularization of the retina and reduce permeability of the blood retinal barrier. The invention also includes a pharmaceutical composition containing the antibody for treating RVO, and provides detailed claims and methods for administering the antibody to patients. [Extracted from the article]